A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

May 28, 2027

Study Completion Date

May 28, 2027

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

LTI-03

Caveolin-1-Scaffolding-Protein-Derived Peptide

DEVICE

Dry Powder Inhaler

Plastiape Monodose RS01 Model 7

DRUG

Placebo

Lactose powder

Trial Locations (2)

The Lung Research Center, LLC, Chesterfield

El Paso Pulmonary Association, El Paso